PBAC's latest decision on Primidone: Recommended with restriction (2019). Considered for Management of grand mal and psychomotor (temporal lobe) epilepsy, focal or Jacksonian seizures, myoclonic jerks and akinetic attacks.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Patients with grand mal, psychomotor (temporal lobe) epilepsy, focal or Jacksonian seizures, myoclonic jerks and akinetic attacks requiring primidone 250 mg tablets.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
BIA only
Budget impact
$170K
Eligible patients/year
14,278
ICER note
Not modelled — this is a temporary supply shortage substitution for an existing listed product, not a new clinical/economic evaluation.